Table 3 |
|||
|
Recommendations taking into account the balance of benefit (pain reduction and function improvement) and harm (adverse event) |
|||
|
Product |
Grade of recommendation |
Quality evidence |
Balance benefit to harm |
|
|
|||
|
Avocado/soybean unsaponifiables |
Strong |
Moderate |
Avocado/soybean unsaponifiables advantageous |
|
Chondroitin sulfate |
Strong |
Moderate |
Chondroitin sulfate advantageous |
|
Diacereine |
Strong |
Moderate |
Diacereine advantageous |
|
Glucosamine sulfate |
Strong |
Moderate |
Glucosamine sulfate advantageous |
|
Hyaluronic acid |
Strong |
Moderate |
Hyaluronic acid advantageous |
|
Oral calcitonin |
Weak |
Low |
Calcitonin not advantageous |
|
Risedronate |
Strong |
High |
Risedronate not advantageous |
|
Strontium ranelate |
Weak |
Very low |
Strontium ranelate advantageous |
|
|
|||
|
Bruyère et al. BMC Musculoskeletal Disorders 2008 9:165 doi:10.1186/1471-2474-9-165 |
|||
